Navigation Links
ReBuilder Medical Technologies, Inc. Expands R&D of New Products
Date:1/8/2008

CHARLES TOWN, W.Va., Jan. 8 /PRNewswire-FirstCall/ -- ReBuilder Medical Technologies, Inc. (Pink Sheets: RBRM), announces new R&D facility.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061128/REBUILDERLOGO )

"We have leased, fitted and established the infrastructure for a new offsite engineering laboratory that will allow us to streamline the process of new product development. This state of the art R&D facility will house both electronic and pharmaceutical laboratories," announced David B. Phillips, Ph.D., CEO of RBRM.

"We have the ability to introduce new products into the market via the web and support the sales of new products through our established customer service department. We will be able to fast-track both electronic and pharmaceutical projects; each new project has the potential to double our current revenues. Our current projections give a release date for new products in the third quarter of 2008," according to Daena Carter, CFO of RBRM.

For more information visit: http://www.rebuildermedical.com, http://www.molluscum.com.

Safe Harbor: This letter contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to successfully implement its turnaround strategy, changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition and pricing. Although the Company believes that the assumptions underlying the forward-looking s
'/>"/>

SOURCE ReBuilder Medical Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine news :

1. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
2. ReBuilder Medical Technologies, Inc. Signs Agreement for Distribution in Maine
3. ReBuilder Medical Technologies, Inc. Increases Staffing by 30% in Three Weeks Due to Increase in Demand for All ReBuilder Medical Products
4. ReBuilder Medical Technologies, Inc. Reports Monthly Sales in 2007 Nearly Doubling Monthly Sales in 2006, Including Record Daily Sales in September 2007
5. ReBuilder Medical Technologies, Inc. Contracts with ETS to Manufacture the Newest Version of its ReBuilder Neuropathy Treatment Device; Expects Sales to Increase 30%
6. ReBuilder Medical Technologies, Inc. Announces Agreement with Internet Marketer Helio Health; Anticipates 12% Additional Profit
7. ReBuilder Medical Technologies, Inc. Announces UK Demand for Safe Molluscum Contagiosum Treatment Leads to Distribution Agreement with UFFE Medical, LTD. Expected 10% Sales Increase.
8. ReBuilder Medical Technologies, Inc. Increases Manufacturing Space to Meet Demand
9. ReBuilder Medical Technologies, Inc. Hires Nurses Exclusively to Provide Customer Support
10. ReBuilder Medical Technologies, Inc. Celebrates Five Years and 50,000th Shipment
11. ReBuilder Medical Technologies, Inc. Announces Record Sales Month
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Circassia Raises GBP15 Million ($25 Million) in Oversubscribed Investment Round 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5Duke University Health System Chooses SSI for Revenue Cycle Claims Management 47794 1Duke University Health System Chooses SSI for Revenue Cycle Claims Management 47794 2Duke University Health System Chooses SSI for Revenue Cycle Claims Management 47794 3Five Cord Blood Transplant Centers in Catalonia and Valencia Join a Study to Test a New Technique to Treat Leukemia and Lymphoma 12449 1Five Cord Blood Transplant Centers in Catalonia and Valencia Join a Study to Test a New Technique to Treat Leukemia and Lymphoma 12449 2Five Cord Blood Transplant Centers in Catalonia and Valencia Join a Study to Test a New Technique to Treat Leukemia and Lymphoma 12449 3Lupus Foundation of America Fosters the Next Generation of Lupus Researchers by Awarding Gina M Finzi Memorial Student Summer Fellowships to Five Stu 4531 1Lupus Foundation of America Fosters the Next Generation of Lupus Researchers by Awarding Gina M Finzi Memorial Student Summer Fellowships to Five Stu 4531 2Lupus Foundation of America Fosters the Next Generation of Lupus Researchers by Awarding Gina M Finzi Memorial Student Summer Fellowships to Five Stu 4531 3